SCHEMBL13643242

SCHEMBL13643242

C[C@H](C#N)Cc1ccc(C(=O)CN(C)C(=O)C(C)(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ACACB O00763 5/20 0.33
MAOB P27338 3/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
NSD2 O96028 1/20 0.32
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2617406 0.79 CTSS (0.43) ATMACACB
SCHEMBL13643238 0.75 GSK3B (0.53) ACACBRAB9A
SCHEMBL13637068 0.74 NPC1 (0.49) MAPTLMNAALDH1A1SMN1; SMN2KDM4E
SCHEMBL2294263 0.73 ALDH1A1 (0.50) MAPTALDH1A1POLBSMN1; SMN2ACACB
SCHEMBL13643097 0.72 TSHR (0.31) ACACB
SCHEMBL8763089 0.70 ESR2 (0.42) CYP1A2CYP3A4CYP2C19ALDH1A1MAOB
SCHEMBL28192730 0.68 NPC1 (0.43) MAPTLMNACYP2D6ACACBRAB9A
SCHEMBL28543134 0.67 KDM4E (0.54) LMNAALDH1A1KDM4EUSP2
SCHEMBL10618893 0.66 TSHR (0.53) MAPTLMNACYP1A2CYP3A4CYP2D6
Diethylamine SCHEMBL2917696 0.66 ACACB (0.47) ALDH1A1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772507-B2 Imidazole-benzamide anti-cancer agents CYTOKINETICS, INC. (US) 2014-07-08 US disclosed
US-20130096315-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS QIAN XIANGPING (US) 2013-04-18 US disclosed
US-20120283287-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2012-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283287-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS KIF5B, KIF2C, PLK1 MAPT 294/4885LMNA 1022/4885CYP1A2 4665/4885
US-20130096315-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS KIF5B, KIF2C, PLK1 MAPT 330/4885LMNA 976/4885CYP1A2 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.